VIICTR Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014 Sep; 15(10):1090-9.
View in:
PubMed
subject areas
Adenine
Administration, Oral
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Kaplan-Meier Estimate
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Recurrence, Local
Patient Selection
Piperidines
Prognosis
Pyrazoles
Pyrimidines
Rituximab
Survival Rate
Treatment Outcome
authors with profiles
HAGOP M KANTARJIAN
ALESSANDRA FERRAJOLI
WILLIAM G WIERDA
XUELIN HUANG
JEFFREY L JORGENSEN
JAN ANDREAS BURGER
NAVEEN GARG